Bank of America
LXEO icon

Bank of America’s Lexeo Therapeutics LXEO Stock Holding History

Bank of America’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.82M Buy
491,532
+331,244
+207% +$2.35M ﹤0.01% 3873
2025
Q4 		$1.59M Buy
160,288
+132,009
+467% +$1.2M ﹤0.01% 4245
2025
Q3 		$188K Buy
28,279
+1,626
+6% +$7.86K ﹤0.01% 6304
2025
Q2 		$107K Buy
26,653
+4,883
+22% +$16.1K ﹤0.01% 6495
2025
Q1 		$75.5K Sell
21,770
-8,606
-28% -$38.1K ﹤0.01% 6614
2024
Q4 		$200K Sell
30,376
-8,409
-22% -$66.2K ﹤0.01% 6124
2024
Q3 		$351K Buy
38,785
+24,134
+165% +$288K ﹤0.01% 5710
2024
Q2 		$235K Buy
14,651
+9,380
+178% +$136K ﹤0.01% 5806
2024
Q1 		$82.6K Sell
5,271
-2,857
-35% -$44.7K ﹤0.01% 6329
2023
Q4 		$109K Buy
+8,128
New +$101K ﹤0.01% 6342

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America's LXEO Position: Q1 2026 in Review

Bank of America increased its Lexeo Therapeutics (LXEO) stake by 207% in Q1 2026, buying an estimated $2.35M and bringing the position to 491,532 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3873.

Bank of America first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Bank of America held 491,532 shares of Lexeo Therapeutics worth $2.82M as of Q1 2026.
  • Bank of America bought 331,244 Lexeo Therapeutics shares in Q1 2026, an estimated $2.35M.
  • Lexeo Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3873 holding.
  • Bank of America first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.